Publication:
Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand

dc.contributor.authorDuangnate Rojanapornen_US
dc.contributor.authorTaweevat Attasethen_US
dc.contributor.authorWimwipa Dieosuthichaten_US
dc.contributor.authorKitikul Leelawongsen_US
dc.contributor.authorSamart Pakakasamaen_US
dc.contributor.authorUsanarat Anurathapanen_US
dc.contributor.authorEkachat Chanthanaphaken_US
dc.contributor.authorSirintara Singhara Na Ayudhayaen_US
dc.contributor.authorRangsima Aroonrochen_US
dc.contributor.authorSuradej Hongengen_US
dc.contributor.otherFaculty of Medicine, Ramathibodi Hospital, Mahidol Universityen_US
dc.date.accessioned2020-10-05T06:36:42Z
dc.date.available2020-10-05T06:36:42Z
dc.date.issued2020-01-01en_US
dc.description.abstract© 2020 Duangnate Rojanaporn et al. Purpose. To investigate the clinical presentations and outcomes of retinoblastoma in relation to the advent of new multimodal treatments in Thailand. Patients and Methods. Retrospective case series. We evaluated the clinical presentation, staging, details of treatment, and treatment outcomes of retinoblastoma patients who were treated at Ramathibodi Hospital, Bangkok, Thailand, between January 1, 2007, and December 31, 2018. The log-rank test was used to explore clinical characteristics and treatment modalities that affected globe salvage and survival curves. Results. This study included 124 eyes of 81 patients with retinoblastoma. Forty-three patients (53.1%) had bilateral retinoblastoma. The median age at diagnosis was 8 months (range, 1-48 months). Of 124 eyes, 9 eyes (7.3%) had extraocular retinoblastoma and 115 eyes (92.7%) had intraocular retinoblastoma, which were classified by the International Classification of Retinoblastoma (ICRB) as group A, 4 eyes (3.5%); group B, 19 eyes (16.5%); group C, 6 eyes (5.2%); group D, 31 eyes (27%); and group E, 56 eyes (47.8%). Treatment included systemic chemotherapy, intra-arterial chemotherapy, ruthenium-106 plaque brachytherapy, external beam radiation therapy, cryotherapy, transpupillary thermotherapy, subtenon chemotherapy, and intravitreal chemotherapy. At the median follow-up period of 38.4 months (range, 0.2-148.2 months), the overall globe salvage rate of intraocular retinoblastoma was 51.7%. For unilateral retinoblastoma, globe salvage rate was 37.5% (group B, 100%; group C, 100%; group D, 50%; and group E, 18.8%). For bilateral intraocular retinoblastoma, the globe salvage rate was 57.8% (group A, 100 %; group B, 94.4%; group C, 100%; group D, 64.7%; and group E, 28.2%). The overall survival rate was 93.8%. Conclusions. Recent advanced treatment modalities have improved the probability of globe salvage. However, enucleation remains an important life-saving intervention in many advanced cases.en_US
dc.identifier.citationJournal of Ophthalmology. Vol.2020, (2020)en_US
dc.identifier.doi10.1155/2020/4231841en_US
dc.identifier.issn20900058en_US
dc.identifier.issn2090004Xen_US
dc.identifier.other2-s2.0-85091699964en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/59241
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85091699964&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleClinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailanden_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85091699964&origin=inwarden_US

Files

Collections